Valeria Smiroldo
Humanitas University
Internal medicineOncologyAdverse effectClinical endpointWild typeHepatocellular carcinomaFOLFOXMaintenance therapyPanitumumabPancreasNeuroendocrine tumorsDiseaseEverolimusMetforminProgression-free survivalAdenocarcinomaPredictive factorIn patientPhases of clinical researchCancer researchColorectal cancerClinical trialMedicineCohort
37Publications
4H-index
116Citations
Publications 37
Newest
In resectable gastric or gastroesophageal junction cancer (GC/GEJC), the powerful positive prognostic effect and the potential predictive value for a lack of benefit from the combination of adjuvant/peri-operative chemotherapy for the MSI-high status was demonstrated. Given the high sensitivity of MSI-high tumors for immunotherapy, exploratory trials showed that combination immunotherapy induces a high rate of complete pathological response (pCR), potentially achieving cancer cure without surger...
Source
Source
Source
Source
#1Eleonora Vitali (Humanitas University)H-Index: 8
#1E. Vitali (Humanitas University)
Last. Andrea Lania (Humanitas University)H-Index: 13
view all 8 authors...
Pancreatic neuroendocrine tumors (Pan-NETs), are heterogeneous neoplasms, whose incidence and prevalence are increasing worldwide. Pan-NETs are characterized by the expression of somatostatin receptors (SSTs). In particular, SST2 is the most widely distributed SST in NETs, thus representing the main molecular target for somatostatin analogs (SSAs). SSAs are currently approved for the treatment of well-differentiated NETs, and radionuclide-labeled SSAs are used for diagnostic and treatment purpos...
Source
#1Matteo Fassan (UNIPD: University of Padua)H-Index: 62
#2Massimo MilioneH-Index: 31
Last. Fotios LoupakisH-Index: 60
view all 31 authors...
Abstract Background Neuroendocrine differentiation has been extensively associated with worse prognosis and to mechanisms of therapy resistance in several epithelial cancers. A high prevalence of neuroendocrine differentiation was recently described in V600EBRAF-mutated (BRAFmt) metastatic colorectal cancers (mCRCs) but no data are available about its prognostic impact in this setting. Methods We assessed synaptophysin immunohistochemical expression in a multi-institutional series of 159 BRAFmt ...
Source
#1Paolo MancaH-Index: 6
#2Salvatore CoralloH-Index: 12
Last. Filippo PietrantonioH-Index: 32
view all 25 authors...
BACKGROUND The routine use of liquid biopsy is not recommended for the choice of initial treatment of patients with metastatic colorectal cancer (mCRC). EXPERIMENTAL DESIGN We included patients with left-sided, RAS/BRAF wild-type, HER2-negative and microsatellite stable mCRC, treated with upfront FOLFOX-panitumumab in the Valentino study. We performed amplicon-based genomic profiling of 14 genes in baseline plasma samples and compared these data with tumor tissue ultra-deep sequencing results. S...
Source
#1Andrea Casadei-Gardini (UniSR: Vita-Salute San Raffaele University)H-Index: 1
#1Andrea Casadei-Gardini (UniSR: Vita-Salute San Raffaele University)H-Index: 11
Last. Stefano Cascinu (UniSR: Vita-Salute San Raffaele University)H-Index: 7
view all 14 authors...
SBA classification is still based on the location of the primary tumor, without genetic information. in the current study, an extensive genetic profile of SBA, was performed in order to identify and quantify targetable alterations for a future precision medicine in SBA. Clinical-pathological information for 24 patients affected by SBA were retrospectively reviewed. Whole genome analysis of the primary tumors was performed by the FOUNDATION Cdx technology. We carried out a functional enrichment a...
Source
#1Paolo MancaH-Index: 6
#2Salvatore CoralloH-Index: 12
Last. Filippo Pietrantonio (University of Milan)H-Index: 32
view all 27 authors...
Abstract Background In patients with metastatic colorectal cancer (mCRC) receiving highly active first-line combination treatments, early tumor shrinkage (ETS) and depth of response (DoR) are associated with survival, but their influence on outcomes during maintenance therapy is unknown. The Valentino study showed inferior PFS in 229 RAS wild-type mCRC patients randomized to panitumumab plus FOLFOX followed by maintenance with panitumumab vs. panitumumab + 5-FU/LV. Patients and methods After bli...
2 CitationsSource
#1Valeria SmiroldoH-Index: 4
#2Alessandro ZerbiH-Index: 57
Last. Andrea LaniaH-Index: 13
view all 12 authors...